Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.

The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.

This statement is based on a regulatory approval from the European Medicines Agency:

MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.

Citation

Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
1998-06-02	European Medicines Agency	Indication received approval from the European Commission.